Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977456 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL17772168 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL525493 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL1806573 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL15585678 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL204043 | 1.00 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL18829403 | 0.89 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| Pyridine SCHEMBL27388694 | 0.87 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL16927642 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1TYRFPR2KMT2A | |
| SCHEMBL8607996 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1TYRFPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321059-A | Tetracyclic compounds for the treatment of Zika virus infection | 吉利德科学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20220402931-A1 | TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3431477-B1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3431477-B1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0915841-A1 | ANILINOPEPTIDE DERIVATIVES | Novartis AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| CN-1216539-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 1999-05-12 | — | — | CN | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998003476-A1 | ANILINOPEPTIDE DERIVATIVES | NOVARTIS AG (CH) | 1998-01-29 | — | — | WO | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402931-A1 | TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTION | ZC3HAV1, ZC3HAV1L, EIF2AK2 | ALDH1A1 1147/4885L3MBTL1 1711/4885TYR 965/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885L3MBTL1 2058/4885TYR 4183/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885L3MBTL1 2058/4885TYR 4183/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ALDH1A1 3925/4885L3MBTL1 2058/4885TYR 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.